rs11025120 - NAV2
Magnitude 4.5 · 1 study on file
Reported associations
-
A molecular pathway analysis informs the genetic risk for arrhythmias during antipsychotic treatment. - International clinical psychopharmacology (2018) · Drago A, Kure Fischer E · PubMed 29064910
Arrhythmias are a frequent and potentially fatal side effect of antipsychotic treatment. Strict ECG monitoring and clinical interviews are the standards used to prevent arrhythmias. A biologic predictive tool is missing. The identification of a genetic makeup at risk of antipsychotic-induced arrhythmias is the aim of the present investigation. The aim of this study was to identify a molecular pathway enriched in single nucleotide polymorphisms associated with antipsychotic-induced QTc modifications. In total, 661 schizophrenic individuals from the CATIE study, M=486 (73.52%), mean age=40.92±11.02, were included. QTc variation was measured as a phase-specific change-created variable. A nested mixed regression for a repeated-measures model served in R for the analysis of the clinical and tr
Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.
Lifestyle context
Concrete actions anchored to the cited research. We do not prescribe, we describe.
Discuss with your doctor
-
Antipsychotic selection with QTc prolongation risk Moderate
rs11025120-T carriers show greater QTc prolongation during antipsychotic therapy
Discuss with prescriber when considering or starting antipsychotics
Screening
-
QTc interval during antipsychotic treatment Moderate
rs11025120-T allele associates with increased QTc prolongation in response to antipsychotics
Baseline ECG and periodic monitoring if taking antipsychotics